Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

202220 citationsJournal Article

Authors

Nicoletta Colombo · Università Cattolica del Sacro Cuore

Coraline Dubot · Università Cattolica del Sacro Cuore

Domenica Lorusso · Università Cattolica del Sacro Cuore

M. Valeria Caceres · Università Cattolica del Sacro Cuore

Kosei Hasegawa · Università Cattolica del Sacro Cuore

Ronnie Shapira‐Frommer · Università Cattolica del Sacro Cuore

Krishnansu S. Tewari

Abstract

(Abstracted from N Engl J Med 2021;385:1856–1867) Platinum-based chemotherapy plus bevacizumab and paclitaxel is the standard first-line therapy for persistent, recurrent, or metastatic cervical cancer. The phase 2 KEYNOTE-158 trial found evidence of a response to pembrolizumab among patients with programmed death ligand-1 (PD-L1) positive cervical cancer.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Endometrial and Cervical Cancer Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Obstetrical & Gynecological Survey

Volume 77, Issue 1, pp. 30-31

DOI: 10.1097/01.ogx.0000805152.09501.f1

Field-Weighted Citation Impact: 1.99